HA Sustainable Infrastructure Capital, Inc. HASI 深 沪
等待开盘 05-21 09:30:00 美东时间
40.21
+0.500
+1.26%
华盛通- 最 高40.57
- 今 开40.14
- 成交量 116.37万股
- 最 低 39.91
- 昨 收 39.71
- 总市值 51.64亿
- 52周最高 44.13
- 市盈率 静 28.54
- 换手率 0.91%
- 52周最低 22.60
- 委 比 -14.29%
- 总股本 1.28亿
- 历史最高 64.175
- 量 比 1.13
- 振 幅 1.66%
- 历史最低 -5.93
- 每 手 1
- 风险率 5.41%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Ameresco And HA Sustainable Infrastructure Capital Joint Venture Neogenyx Fuels Awards Anaergia C$58M U.S. RNG Infrastructure Contract To Deploy Large-Scale Anaerobic Digestion Systems Over Next 2 Years
Partnership with Neogenyx Fuels reinforces Anaergia's role as a provider of scalable renewable natural gas infrastructure solutionsAnaergia Inc. ("Anaergia" or the "Company") (TSX:ANRG) (OTCQX:ANRGF), through its
05-19 23:14
美股大行评级 | 富国银行上调英伟达目标价从265美元升至315美元；Alamar、AEVEX获多家大行首予“买入”评级
今日重点评级关注：Needham：维持Artiva Biotherapeutics"买入"评级，目标价从18美元升至41美元；HC Wainwright & Co.：维持SAB Biotherapeutics"买入"评级，目标价从7美元升至10美元
05-13 11:46
美股大行评级 | Arxis、Madison Air获多家大行首予买入评价！潜在涨幅441.87%！Caribou Biosciences获HC Wainwright & Co.升目标价至11美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Caribou Biosciences"买入"评级，目标价从9美元升至11美元；康托·菲茨杰拉德：维持Artiva Biotherapeutics"超配"评级，目标价从10美元升至40美元
05-12 12:36
美股大行评级 | 爱彼迎、Affirm、CoreWeave、Datadog、微芯科技等获多家大行上调目标价；HubSpot惨遭14家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从15美元升至35美元；韦德布什：维持Cullinan Therapeutics"跑赢大市"评级，目标价从36美元升至37美元
05-11 15:43
RBC Capital Maintains Outperform on HASI, Raises Price Target to $48
RBC Capital analyst Christopher Dendrinos maintains HASI (NYSE:HASI) with a Outperform and raises the price target from $43 to $48.
05-09 00:57
美股大行评级 | 瑞银大幅上调西部数据、希捷科技目标价！汇丰银行上调英特尔评级至"买入"，目标价从50美元升至95美元
今日重点评级关注：HC Wainwright & Co.：维持Century Therapeutics"买入"评级，目标价从2美元升至5美元；Oppenheimer：维持Climb Bio"跑赢大市"评级，目标价从10美元升至18美元
04-22 12:41
Citigroup Maintains Buy on HASI, Raises Price Target to $50
Citigroup analyst Vikram Bagri maintains HASI (NYSE:HASI) with a Buy and raises the price target from $36 to $50.
04-22 02:16
美股大行评级 | 高盛首予PayPay“买入”评级；神经分泌生物科学获花旗等多家机构上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Enlivex"买入"评级，目标价从13美元升至20美元；韦德布什：维持FuboTV"跑赢大市"评级，目标价从3.5美元升至24美元
04-08 18:35
Morgan Stanley Maintains Overweight on HASI, Raises Price Target to $54
Morgan Stanley analyst Robert Kad maintains HASI (NYSE:HASI) with a Overweight and raises the price target from $47 to $54.
04-07 23:01
Hannon Armstrong publishes investor presentation on USD 16.1 billion managed sustainable infrastructure assets
Hannon Armstrong publishes investor presentation on USD 16.1 billion managed sustainable infrastructure assets Hannon Armstrong said its equity market capitalization was about USD 5 billion and its dividend yield was about 5%. The company reported 2025 GAAP EPS of USD 1.91 and adjusted EPS of USD 2.
03-12 15:24
